RxDoctor Payments DataLook up a doctor →

Gregory Ball, MD

Pain Medicine · Chattanooga, TNNPI 1609832229

Payments from drug & device makers

$35,370in general payments, 2019–2025

Across 693 payments — averaging $51.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$11K
  • Boston Scientific$5K
  • Medtronic$4K
  • MML US, Inc.$3K
  • Relievant Medsystems, Inc.$2K
  • Saluda Medical Americas, Inc.$2K
  • plus $9K from 45 others

What the payments were for

  • Speaking & faculty fees$6,07517%
  • Travel & lodging$4,84914%
  • Food & beverage$24,42569%
  • Education$200%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$35,370 in reported general payments places this provider in the 90th percentile of 112 pain medicine providers in Tennessee.

See all pain medicine providers in Tennessee

Medicare billing

Part B allowed, 2024
$192,459
Medicare patients
285
Services billed
2,907

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OxycontinOxycodone Hcl30$20,583
Xtampza ErOxycodone Myristate28$18,986
NucyntaTapentadol Hcl25$18,581
ButransBuprenorphine22$10,072
Nucynta ErTapentadol Hcl13$9,777
Buprenorphine37$7,942
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen272$7,525
BelbucaBuprenorphine Hcl11$7,461
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen261$6,822
LinzessLinaclotide11$5,588
MovantikNaloxegol Oxalate11$4,355
Gabapentin250$3,566
Lidocaine36$3,485
Oxycodone Hcl199$3,325
Morphine Sulfate ErMorphine Sulfate100$2,433

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er, Nucynta, Nucynta Er, Belbuca$160$54,80577 claims
Hikma Pharmaceuticals USABuprenorphine$15$7,94237 claims
AbbVieLinzess$744$5,58811 claims
Redhill Biopharma Inc.Movantik$85$4,35511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 112 pain medicine providers in Tennessee.

Other pain medicine in Chattanooga

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →